Cardlytics, Inc. Financial Summary

Quick Answer

Cardlytics, Inc. reported Total Revenue of $233.27 million for fiscal year 2025.

Cardlytics, Inc. — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $233.27M
-16.2%
$278.30M
-10.0%
$309.20M
+3.6%
$298.54M
+11.8%
$267.12M
+42.9%
$186.89M
-11.2%
Net Income -$103.49M
+45.3%
-$189.30M
-40.5%
-$134.70M
+71.0%
-$465.26M
-261.9%
-$128.56M
-132.0%
-$55.42M
-223.3%
Diluted EPS -$1.95
+50.1%
-$3.91
-6.0%
-$3.69
+73.5%
-$13.92
Total Assets $285.64M
-27.3%
$392.71M
-31.6%
$574.14M
-16.9%
$691.24M
-45.3%
$1.26B
+199.1%
$422.54M
+88.4%
Cash and Equivalents $48.72M
-25.7%
$65.59M
-28.6%
$91.83M
-24.7%
$121.91M
-47.8%
$233.47M
-20.4%
$293.24M
+180.7%
Long-Term Debt
Stockholders Equity -$6.51M
-109.3%
$69.99M
-48.1%
$134.80M
-36.3%
$211.60M
-69.4%
$690.70M
+339.4%
$157.19M
+9.7%
R&D Expense $39.77M
-19.8%
$49.61M
-3.4%
$51.35M
-5.7%
$54.44M
+42.9%
$38.10M
+117.3%
$17.53M
+49.9%
Operating Income -$101.82M
+47.9%
-$195.50M
-44.1%
-$135.67M
+70.4%
-$457.78M
-273.4%
-$122.60M
-127.4%
-$53.92M
-211.2%
Shares Outstanding 54.51M
+6.4%
51.26M
+29.0%
39.73M

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $52.03M -22.4% -17.7%
Net Income September 30, 2025 -$72.67M +49.9% -682.9%
Diluted EPS September 30, 2025 -$1.36 +53.1% -655.6%
Total Assets September 30, 2025 $292.81M -26.7% -18.9%
Cash and Equivalents September 30, 2025 $43.96M -34.4% -6.0%
Long-Term Debt September 30, 2020 $0.00 -100.0%
Stockholders Equity September 30, 2025 -$4.70M -106.7% -108.0%
R&D Expense September 30, 2025 $8.80M -33.3% -22.1%
Operating Income September 30, 2025 -$68.85M +53.6% -438.4%
Shares Outstanding September 30, 2025 51.26M +29.0% +0.0%
  • Cardlytics, Inc. reported Total Revenue of $233.27 million for fiscal year 2025.
  • Cardlytics, Inc. showed a decrease of -16.2% in Total Revenue compared to the prior fiscal year.
  • Cardlytics, Inc. reported Net Income of -$103.49 million for fiscal year 2025.
  • Cardlytics, Inc. showed an increase of +45.3% in Net Income compared to the prior fiscal year.
  • Cardlytics, Inc. reported Diluted EPS of $1.95 per share (loss) for fiscal year 2025.
  • Cardlytics, Inc. showed an increase of +50.1% in Diluted EPS compared to the prior fiscal year.
  • Cardlytics, Inc. reported Total Assets of $285.64 million for fiscal year 2025.
  • Cardlytics, Inc. showed a decrease of -27.3% in Total Assets compared to the prior fiscal year.
  • Cardlytics, Inc. reported Cash and Equivalents of $48.72 million for fiscal year 2025.
  • Cardlytics, Inc. showed a decrease of -25.7% in Cash and Equivalents compared to the prior fiscal year.
  • Cardlytics, Inc. reported Long-Term Debt of $13.0 thousand for fiscal year 2019.
  • Cardlytics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
  • Cardlytics, Inc. reported Stockholders Equity of -$6.51 million for fiscal year 2025.
  • Cardlytics, Inc. showed a decrease of -109.3% in Stockholders Equity compared to the prior fiscal year.
  • Cardlytics, Inc. reported R&D Expense of $39.77 million for fiscal year 2025.
  • Cardlytics, Inc. showed a decrease of -19.8% in R&D Expense compared to the prior fiscal year.
  • Cardlytics, Inc. reported Operating Income of -$101.82 million for fiscal year 2025.
  • Cardlytics, Inc. showed an increase of +47.9% in Operating Income compared to the prior fiscal year.
  • Cardlytics, Inc. reported Shares Outstanding of 54.51 million shares for fiscal year 2025.
  • Cardlytics, Inc. showed an increase of +6.4% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment